PURPOSE: As a follow-up to previous studies showing that human cortical neural progenitor cells (hNPC(ctx)) can sustain vision for at least 70 days after injection into the subretinal space of Royal College of Surgeons (RCS) rats, the authors examined how functional rescue is preserved over long periods and how this relates to retinal integrity and donor cell survival. METHODS: Pigmented dystrophic RCS rats (n = 15) received unilateral subretinal injections of hNPC(ctx) at postnatal day (P) 21; control rats (n = 10) received medium alone and were untreated. All animals were maintained on oral cyclosporine A. Function was monitored serially by measuring acuity (using an optomotor test) and luminance thresholds (recording from the superior colliculus) at approximately P90, P150, and P280. Eyes were processed for histologic study after functional tests. RESULTS: Acuity and luminance thresholds were significantly better in hNPC(ctx)-treated animals than in controls (P < 0.001) at all time points studied. Acuity was greater than 90%, 82%, and 37% of normal at P90, P150, and P270, whereas luminance thresholds in the area of best rescue remained similar the whole time. Histologic studies revealed substantial photoreceptor rescue, even up to P280, despite progressive deterioration in rod and cone morphology. Donor cells were still present at P280, and no sign of donor cell overgrowth was seen. CONCLUSIONS: Long-term rescue of function and associated morphologic substrates was seen, together with donor cell survival even in the xenograft paradigm. This is encouraging when exploring further the potential for the application of hNPC(ctx) in treating retinal disease.
PURPOSE: As a follow-up to previous studies showing that human cortical neural progenitor cells (hNPC(ctx)) can sustain vision for at least 70 days after injection into the subretinal space of Royal College of Surgeons (RCS) rats, the authors examined how functional rescue is preserved over long periods and how this relates to retinal integrity and donor cell survival. METHODS:Pigmented dystrophic RCSrats (n = 15) received unilateral subretinal injections of hNPC(ctx) at postnatal day (P) 21; control rats (n = 10) received medium alone and were untreated. All animals were maintained on oral cyclosporine A. Function was monitored serially by measuring acuity (using an optomotor test) and luminance thresholds (recording from the superior colliculus) at approximately P90, P150, and P280. Eyes were processed for histologic study after functional tests. RESULTS: Acuity and luminance thresholds were significantly better in hNPC(ctx)-treated animals than in controls (P < 0.001) at all time points studied. Acuity was greater than 90%, 82%, and 37% of normal at P90, P150, and P270, whereas luminance thresholds in the area of best rescue remained similar the whole time. Histologic studies revealed substantial photoreceptor rescue, even up to P280, despite progressive deterioration in rod and cone morphology. Donor cells were still present at P280, and no sign of donor cell overgrowth was seen. CONCLUSIONS: Long-term rescue of function and associated morphologic substrates was seen, together with donor cell survival even in the xenograft paradigm. This is encouraging when exploring further the potential for the application of hNPC(ctx) in treating retinal disease.
Authors: P J Coffey; S Girman; S M Wang; L Hetherington; D J Keegan; P Adamson; J Greenwood; R D Lund Journal: Nat Neurosci Date: 2002-01 Impact factor: 24.884
Authors: A Gal; Y Li; D A Thompson; J Weir; U Orth; S G Jacobson; E Apfelstedt-Sylla; D Vollrath Journal: Nat Genet Date: 2000-11 Impact factor: 38.330
Authors: P M D'Cruz; D Yasumura; J Weir; M T Matthes; H Abderrahim; M M LaVail; D Vollrath Journal: Hum Mol Genet Date: 2000-03-01 Impact factor: 6.150
Authors: S Wang; M P Villegas-Pérez; T Holmes; J M Lawrence; M Vidal-Sanz; N Hurtado-Montalbán; R D Lund Journal: Curr Eye Res Date: 2003-09 Impact factor: 2.424
Authors: Melissa K Jones; Bin Lu; Dawn Zhaohui Chen; Weston R Spivia; Augustus T Mercado; Alexander V Ljubimov; Clive N Svendsen; Jennifer E Van Eyk; Shaomei Wang Journal: Proteomics Date: 2019-01-02 Impact factor: 3.984
Authors: Jingyu Yao; Kecia L Feathers; Hemant Khanna; Debra Thompson; Catherine Tsilfidis; William W Hauswirth; John R Heckenlively; Anand Swaroop; David N Zacks Journal: Invest Ophthalmol Vis Sci Date: 2011-03-01 Impact factor: 4.799
Authors: Biju B Thomas; Danhong Zhu; Tai-Chi Lin; Young Chang Kim; Magdalene J Seiler; Juan Carlos Martinez-Camarillo; Bin Lin; Yousuf Shad; David R Hinton; Mark S Humayun Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-09-13 Impact factor: 3.117
Authors: T Michael Nork; Christopher J Murphy; Charlene B Y Kim; James N Ver Hoeve; Carol A Rasmussen; Paul E Miller; Hugh D Wabers; Michael W Neider; Richard R Dubielzig; Ryan J McCulloh; Brian J Christian Journal: Arch Ophthalmol Date: 2011-09-12
Authors: Peter J Francis; Shaomei Wang; Yi Zhang; Anna Brown; Thomas Hwang; Trevor J McFarland; Brett G Jeffrey; Bin Lu; Lynda Wright; Binoy Appukuttan; David J Wilson; J Timothy Stout; Martha Neuringer; David M Gamm; Raymond D Lund Journal: Invest Ophthalmol Vis Sci Date: 2009-02-21 Impact factor: 4.799
Authors: Shaomei Wang; Bin Lu; Sergei Girman; Jie Duan; Trevor McFarland; Qing-shuo Zhang; Markus Grompe; Grazyna Adamus; Binoy Appukuttan; Raymond Lund Journal: PLoS One Date: 2010-02-15 Impact factor: 3.240
Authors: Dhruv Sareen; Erin McMillan; Allison D Ebert; Brandon C Shelley; Julie A Johnson; Lorraine F Meisner; Clive N Svendsen Journal: PLoS One Date: 2009-10-29 Impact factor: 3.240